AMP.L Regulatory News (AMP)

Amphion Innovations plc

 ("Amphion" or "the Company")

Board Change

London and New York: 5 September 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses announces the appointment of Stephen Austin as an additional non-executive director effective immediately. Following a career as a corporate lawyer, qualified executive and corporate stockbroker, Stephen is now the Chief Investment Officer of Plumtree Capital Limited, an FCA authorised corporate finance firm.

Stephen will join the Compensation Committee (as chairman) and the Audit Committee.

Save as disclosed below, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.

Stephen Michael Austin (age 51) is, or has been in the previous five years, a director or partner, of the following companies:

Stephen Austin currently owns 300,000 warrants in the Company. The warrants have an exercise price of 3.5 pence and expire 28 July 2019.

Richard Morgan, CEO, commented: "We have worked with Stephen for four years on a range of projects including the successful AIM IPOs of Motif Bio and Polarean Imaging and now welcome him to the Board."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

For further information please contact:

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

On the web: www.amphionplc.com